文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

危重患者吸入依前列醇输送系统意外中断的发生率及不良后果

Unexpected Interruptions in the Inhaled Epoprostenol Delivery System: Incidence of Adverse Sequelae and Therapeutic Consequences in Critically Ill Patients.
PubMed 文献 · Crit Care Explor · 2021-10-14
一句话结论吸入依前列醇经振动网孔雾化器输送时约6.3%发生意外中断,多致严重心肺不良事件,需立即识别并干预。

该回顾性研究分析了2019年斯坦福大学医院433例患者共493次吸入依前列醇治疗,主要适应证为右心功能障碍(79.9%)和低氧血症(18.7%)。意外输送中断发生31次(6.3%),中位治疗2天后出现,多发生于机械通气(61.3%)和高流量鼻导管(35.5%)患者。中断后不良事件包括肺动脉压升高、体循环低血压、低氧血症、中心静脉压升高及心脏骤停,93.5%为CTCAE 3-4级。多数中断需启动吸入一氧化氮等治疗干预,提示床旁需警惕输送系统中断风险。

要点

  • 吸入依前列醇经振动网孔雾化器输送时意外中断发生率6.3%(31/493次给药),中位发生时间为治疗第2天(IQR 2-5天)。
  • 中断时呼吸支持模式:机械通气61.3%、高流量鼻导管35.5%、无创正压通气3.2%。
  • 中断后不良事件包括肺动脉压升高(12例)、体循环低血压(8例)、低氧血症(8例)、中心静脉压升高(4例)和心脏骤停(1例),93.5%为CTCAE 3-4级。
  • 中断后治疗干预:启动吸入一氧化氮21例,增加血管活性药物2例,增加呼吸支持2例。
  • 因依赖电子病历记录,真实中断发生率及需干预率可能被低估;突然中断可致严重心肺功能失代偿,罕见死亡。

适用人群与场景

  • 2019年在斯坦福大学医院(605张床三级医疗中心)接受吸入依前列醇治疗的危重患者,共433例患者493次给药。
  • 主要适应证为右心功能障碍(394例,79.9%)和低氧血症(92例,18.7%)。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 吸入依前列醇输送意外中断可导致肺动脉压升高、体循环低血压、低氧血症、中心静脉压升高及心脏骤停,需立即识别并处理。
  • 中断后多数需治疗干预,包括启动吸入一氧化氮(21例)、增加血管活性药物(2例)或增加呼吸支持(2例)。

研究设计与关键结果

  • 回顾性研究,单中心(斯坦福大学医院),2019年共493次吸入依前列醇给药,433例独特患者。
  • 意外输送中断发生31次(6.3%),中位治疗至中断时间2天(IQR 2-5天)。
  • 中断时呼吸支持:机械通气61.3%,高流量鼻导管35.5%,无创正压通气3.2%。
  • 不良事件:肺动脉压升高12例,体循环低血压8例,低氧血症8例,中心静脉压升高4例,心脏骤停1例;93.5%为CTCAE 3-4级。
  • 治疗干预:启动吸入一氧化氮21例,增加血管活性药物2例,增加呼吸支持2例。

证据类型、等级与局限

  • 证据类型:回顾性综述和分析(单中心)。
  • 局限:依赖电子病历记录识别和记录意外中断,真实发生率及需干预率未知;原文未提及证据等级。

对床旁实践的改变

  • 对接受吸入依前列醇(经振动网孔雾化器)的危重患者,应警惕输送系统意外中断,尤其在治疗第2天左右及机械通气或高流量鼻导管支持患者中。
  • 突然中断可致严重心肺功能失代偿,需床旁密切监测并及时干预(如启动吸入一氧化氮、增加血管活性药物或呼吸支持)。
  • 因依赖电子病历记录,实际中断发生率可能被低估,临床应主动排查输送系统异常。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVES: Inhaled epoprostenol is a continuously delivered selective pulmonary vasodilator that is used in patients with refractory hypoxemia, right heart failure, and postcardiac surgery pulmonary hypertension. Published data suggest that inhaled epoprostenol administration via vibrating mesh nebulizer systems may lead to unexpected interruptions in drug delivery. The frequency of these events is unknown. The objective of this study was to describe the incidence and clinical consequences of unexpected interruption in critically ill patients.

DESIGN: Retrospective review and analysis.

SETTING: Stanford University Hospital, a 605-bed tertiary care center.

PATIENTS: Patients receiving inhaled epoprostenol in 2019.

INTERVENTIONS: No interventions.

MEASUREMENTS AND MAIN RESULTS: Clinical indication, duration of inhaled epoprostenol delivery, mode of respiratory support, and documented unexpected interruption. In 2019, there were 493 administrations of inhaled epoprostenol in 433 unique patients. Primary indications for inhaled epoprostenol were right heart dysfunction (n = 394; 79.9%) and hypoxemia (n = 92; 18.7%). Unexpected delivery interruptions occurred in 31 administrations (6.3%). Median duration of therapy prior to unexpected interruption was 2 days (interquartile range, 2-5 d). Respiratory support at the time of unexpected interruption was mechanical ventilation (61.3%), high-flow nasal cannula (35.5%), and noninvasive positive pressure ventilation (3.2%). Adverse sequelae of unexpected interruption included elevated pulmonary artery pressures (n = 12), systemic hypotension (n = 8), hypoxemia (n = 8), elevated central venous pressure (n = 4), and cardiac arrest (n = 1). Therapeutic interventions following unexpected interruption included initiation of inhaled nitric oxide (n = 21), increase in vasoactive medication (n = 2), and increase in respiratory support (n = 2). Most of the adverse events were Common Terminology Criteria for Adverse Events grade 3 and 4 (93.5%).

CONCLUSIONS: A retrospective review of patients receiving inhaled epoprostenol via vibrating mesh nebulizer in 2019 revealed interruptions in 6.3% of administrations with most of these interruptions requiring therapeutic intervention. The true incidence of unexpected interruption and subsequent rate of unexpected interruption's requiring intervention is unknown due to the reliance on unexpected interruption identification and subsequent documentation in the electronic medical record. Sudden interruption in inhaled epoprostenol delivery can result in severe cardiopulmonary compromise, and on rare occasion, death.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Block JM, Madhok J, Owyang CG, et al. Unexpected Interruptions in the Inhaled Epoprostenol Delivery System: Incidence of Adverse Sequelae and Therapeutic Consequences in Critically Ill Patients. Crit Care Explor. 2021. PMID: 34671745. doi:10.1097/CCE.0000000000000548

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。